![PDF) Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): Protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial PDF) Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): Protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial](https://i1.rgstatic.net/publication/337994161_Topical_sirolimus_01_for_treating_cutaneous_microcystic_lymphatic_malformations_in_children_and_adults_TOPICAL_Protocol_for_a_multicenter_phase_2_within-person_randomized_double-blind_vehicle-controll/links/5df97de692851c8364854c73/largepreview.png)
PDF) Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): Protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial
![Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial | Dermatology and Therapy Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial | Dermatology and Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13555-020-00387-7/MediaObjects/13555_2020_387_Fig8_HTML.png)
Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial | Dermatology and Therapy
![Baseline characteristics of 33 patients receiving sirolimus gel for... | Download Scientific Diagram Baseline characteristics of 33 patients receiving sirolimus gel for... | Download Scientific Diagram](https://www.researchgate.net/publication/341848889/figure/tbl1/AS:899773552922625@1591534140768/Baseline-characteristics-of-33-patients-receiving-sirolimus-gel-for-facial-angiofibroma.png)
Baseline characteristics of 33 patients receiving sirolimus gel for... | Download Scientific Diagram
![Topical rapamycin treatment alleviates the rosacea-associated symptoms... | Download Scientific Diagram Topical rapamycin treatment alleviates the rosacea-associated symptoms... | Download Scientific Diagram](https://www.researchgate.net/publication/350170087/figure/fig3/AS:1022679666675712@1620837241052/Topical-rapamycin-treatment-alleviates-the-rosacea-associated-symptoms-in-rosacea.png)
Topical rapamycin treatment alleviates the rosacea-associated symptoms... | Download Scientific Diagram
![Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial | Trials | Full Text Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial | Trials | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13063-019-3767-8/MediaObjects/13063_2019_3767_Fig1_HTML.png)
Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial | Trials | Full Text
![A case of microcystic lymphatic malformation successfully treated with topical sirolimus - Çalışkan - 2018 - Dermatologic Therapy - Wiley Online Library A case of microcystic lymphatic malformation successfully treated with topical sirolimus - Çalışkan - 2018 - Dermatologic Therapy - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/6675f8f0-7e4c-4655-bb9d-0d387a4e58f9/dth12673-fig-0001-m.jpg)
A case of microcystic lymphatic malformation successfully treated with topical sirolimus - Çalışkan - 2018 - Dermatologic Therapy - Wiley Online Library
![Polymeric micelle formulations for the cutaneous delivery of sirolimus: A new approach for the treatment of facial angiofibromas in tuberous sclerosis complex - ScienceDirect Polymeric micelle formulations for the cutaneous delivery of sirolimus: A new approach for the treatment of facial angiofibromas in tuberous sclerosis complex - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S037851732100541X-ga1.jpg)
Polymeric micelle formulations for the cutaneous delivery of sirolimus: A new approach for the treatment of facial angiofibromas in tuberous sclerosis complex - ScienceDirect
![Long‐term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients | Semantic Scholar Long‐term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/42346552f5fb5eb83b3386cef541443eb162028d/5-Figure2-1.png)
Long‐term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients | Semantic Scholar
![Rapamycin Skin Cream - US Pharmacy that is Selling it (prescription needed) - Rapamycin Longevity News Rapamycin Skin Cream - US Pharmacy that is Selling it (prescription needed) - Rapamycin Longevity News](https://www.rapamycin.news/uploads/default/original/2X/7/7712f90c5a4ddd0354f8e7fac7a25bb847e6618d.jpeg)
Rapamycin Skin Cream - US Pharmacy that is Selling it (prescription needed) - Rapamycin Longevity News
![Rapamycin: Rapamycin, mTOR, Autophagy & Treating mTOR Syndrome: Pelton, Ross: 9781607660156: Amazon.com: Books Rapamycin: Rapamycin, mTOR, Autophagy & Treating mTOR Syndrome: Pelton, Ross: 9781607660156: Amazon.com: Books](https://images-na.ssl-images-amazon.com/images/I/51IoH6T0RcL._AC_UL600_SR600,600_.jpg)
Rapamycin: Rapamycin, mTOR, Autophagy & Treating mTOR Syndrome: Pelton, Ross: 9781607660156: Amazon.com: Books
![Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial | GeroScience Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial | GeroScience](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs11357-019-00113-y/MediaObjects/11357_2019_113_Fig3_HTML.png)
Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial | GeroScience
![Effects of the concurrent use of the 0.2% sirolimus gel and topical... | Download Scientific Diagram Effects of the concurrent use of the 0.2% sirolimus gel and topical... | Download Scientific Diagram](https://www.researchgate.net/publication/341253931/figure/fig1/AS:888973064949760@1588959103120/Effects-of-the-concurrent-use-of-the-02-sirolimus-gel-and-topical-moisturizers-Time.png)
Effects of the concurrent use of the 0.2% sirolimus gel and topical... | Download Scientific Diagram
![Healthspan Research Review | Inhibiting Skin Senescence with Topical Rapamycin (Sirolimus): A Novel Approach to Anti-Aging Skincare Healthspan Research Review | Inhibiting Skin Senescence with Topical Rapamycin (Sirolimus): A Novel Approach to Anti-Aging Skincare](https://gethealthspan.com/_gatsby/image/5a85e05f6733a37ec44d984b16f0e65a/867ec087ecce9a30eeb5efc92b7ae646/Group%2035.png?u=https%3A%2F%2Fimages.ctfassets.net%2Fzvzqa1d1gh0f%2F20YLDb4rMvBCJwsK74RIHV%2F4adef60b556239d1a69290d8c90756f0%2FGroup_35.png&a=w%3D225%26h%3D238%26fit%3Dcrop%26crop%3Dcenter%26fm%3Dpng%26q%3D75&cd=2023-04-30T01%3A09%3A33.917Z)
Healthspan Research Review | Inhibiting Skin Senescence with Topical Rapamycin (Sirolimus): A Novel Approach to Anti-Aging Skincare
![Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial | Dermatology and Therapy Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial | Dermatology and Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13555-020-00387-7/MediaObjects/13555_2020_387_Fig6_HTML.png)
Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial | Dermatology and Therapy
![Sirolimus-Coated Balloon in an All-Comer Population of Coronary Artery Disease Patients: The EASTBOURNE Prospective Registry | JACC: Cardiovascular Interventions Sirolimus-Coated Balloon in an All-Comer Population of Coronary Artery Disease Patients: The EASTBOURNE Prospective Registry | JACC: Cardiovascular Interventions](https://www.jacc.org/cms/asset/03e76cf8-9fa2-48d2-bcb0-e581e8fc9068/fx1.jpg)
Sirolimus-Coated Balloon in an All-Comer Population of Coronary Artery Disease Patients: The EASTBOURNE Prospective Registry | JACC: Cardiovascular Interventions
![Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial | Trials | Full Text Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial | Trials | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13063-019-3767-8/MediaObjects/13063_2019_3767_Fig2_HTML.png)
Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial | Trials | Full Text
![Biomedicines | Free Full-Text | Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis Biomedicines | Free Full-Text | Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis](https://www.mdpi.com/biomedicines/biomedicines-10-00826/article_deploy/html/images/biomedicines-10-00826-g002-550.jpg)
Biomedicines | Free Full-Text | Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis
![Long‐term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients | Semantic Scholar Long‐term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/42346552f5fb5eb83b3386cef541443eb162028d/7-Figure4-1.png)
Long‐term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients | Semantic Scholar
![PDF) Bioprocess Engineering Aspects of Rapamycin (Sirolimus) Production: A Review on Past Achievements and Recent Perspectives PDF) Bioprocess Engineering Aspects of Rapamycin (Sirolimus) Production: A Review on Past Achievements and Recent Perspectives](https://i1.rgstatic.net/publication/281591148_Bioprocess_Engineering_Aspects_of_Rapamycin_Sirolimus_Production_A_Review_on_Past_Achievements_and_Recent_Perspectives/links/5605290008aea25fce321c12/largepreview.png)
PDF) Bioprocess Engineering Aspects of Rapamycin (Sirolimus) Production: A Review on Past Achievements and Recent Perspectives
![Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial | Dermatology and Therapy Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial | Dermatology and Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs13555-020-00387-7/MediaObjects/13555_2020_387_Fig5_HTML.jpg)